Q9986 — Injection, hydroxyprogesterone caproate, (makena), 10 mg
Q9986 is a HCPCS Level II code for injection, hydroxyprogesterone caproate, (makena), 10 mg. It belongs to the Temporary Codes section. It was terminated on December 31, 2017 and is not valid on new claims.
This code has been terminated
CMS terminated Q9986 on December 31, 2017. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for Q9986
- Long descriptor
- Injection, hydroxyprogesterone caproate, (makena), 10 mg
- Short descriptor
- Makena, 10 mg
- Added
- July 1, 2017
- Terminated
- December 31, 2017
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to Q9986
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If Q9986 is not quite right, the correct code is very often within a few positions of it.
- Q9978Netupitant 300 mg and palonosetron 0.5 mgterminated
- Q9979Injection, alemtuzumab, 1 mgterminated
- Q9980Hyaluronan or derivative, genvisc 850, for intra-articular injection, 1 mgterminated
- Q9981Rolapitant, oral, 1 mgterminated
- Q9982Flutemetamol f18, diagnostic, per study dose, up to 5 millicuries
- Q9983Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries
- Q9984Levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mgterminated
- Q9985Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mgterminated
- Q9987Pathogen(s) test for plateletsterminated
- Q9988Platelets, pheresis, pathogen-reduced, each unitterminated
- Q9989Ustekinumab, for intravenous injection, 1 mgterminated
- Q9991Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg
- Q9992Injection, buprenorphine extended-release (sublocade), greater than 100 mg
- Q9993Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mgterminated
- Q9994In-line cartridge containing digestive enzyme(s) for enteral feeding, eachterminated
- Q9995Injection, emicizumab-kxwh, 0.5 mgterminated
Questions about Q9986
What is HCPCS code Q9986?
Q9986 is a HCPCS Level II code for injection, hydroxyprogesterone caproate, (makena), 10 mg. It sits in the Temporary Codes section.
Does Medicare cover Q9986?
The CMS HCPCS file marks Q9986 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is Q9986 still valid?
No. Q9986 was terminated on December 31, 2017 and should not be used on new claims.